Harrow Health, Inc. (HROW)
Market Cap | 637.71M |
Revenue (ttm) | 88.60M |
Net Income (ttm) | -14.09M |
Shares Out | 29.97M |
EPS (ttm) | -0.51 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 79,016 |
Open | 21.00 |
Previous Close | 20.80 |
Day's Range | 20.95 - 21.67 |
52-Week Range | 5.40 - 22.35 |
Beta | 0.16 |
Analysts | Buy |
Price Target | 23.26 (+9.1%) |
Earnings Date | May 4, 2023 |
About HROW
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commerc... [Read more]
Full Company ProfileFinancial Performance
In 2022, Harrow Health's revenue was $88.60 million, an increase of 22.24% compared to the previous year's $72.48 million. Losses were -$14.09 million, -23.77% less than in 2021.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for HROW stock is "Buy." The 12-month stock price forecast is $23.26, which is an increase of 9.10% from the latest price.
News

Harrow (HROW) is on the Move, Here's Why the Trend Could be Sustainable
Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

B. Riley Leads Financing to Support Harrow Health Acquisition
LOS ANGELES , March 28, 2023 /PRNewswire/ -- B. Riley Financial, Inc. (NASDAQ: RILY) ("B.

Harrow Announces New $100 Million Secured Credit Facility with Oaktree
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it has entered into a $100 million secured credit financing agre...

HARROW HEALTH INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options
NEW YORK , March 25, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Harrow Health, Inc. ("Harrow Health" or the "Company"...

Harrow Announces Fourth Quarter and Year-End 2022 Financial Results
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced results for the fourth quarter and year ended December 31, 2022. The ...

HARROW HEALTH SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options
NEW YORK , March 18, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Harrow Health, Inc. ("Harrow Health" or the "Company")...

ROSEN, NATIONAL TRIAL COUNSEL, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM
NEW YORK , March 17, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Harrow Health, Inc. ...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow Health, Inc. - HROW
NEW YORK , March 13, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harrow Health, Inc. ("Harrow" or the "Company") (NASDAQ: HROW). Such investors are advised to ...

Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3%
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved ...

HARROW HEALTH SHAREHOLDER ACTION REMINDER : Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options
NEW YORK , March 11, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Harrow Health, Inc. ("Harrow Health" or the "Company"...

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM
NEW YORK , March 10, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Harrow Health, Inc. ...

Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory...

ROSEN, LEADING INVESTOR COUNSEL, Encourages Harrow Health, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM
NEW YORK , March 2, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Harrow Health, Inc. (...

Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the fourth quarter and...

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Harrow Health...

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Harrow Health, Inc. (“Harrow” or the “Compan...

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
BENSALEM, Pa. , Feb. 25, 2023 /PRNewswire/ -- Law Offices of Howard G.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Harrow Health, In...

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Harrow Health, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW) investors concerning the Company's...

The Law Offices of Frank R. Cruz Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Harrow Health, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW) on behalf of investors concerning the Compan...

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)---- $HROW #HROW--The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)---- $HROW #HROW--The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc.

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation – HROW, HROWL, HROWM
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Harrow Health, Inc. (NASDAQ: H...

Harrow Launches Next-Generation Compounded Atropine Formulations
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the launch of its patent-pending, next-generation compounded Atropine...

Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has issued a permanen...